Introduction

Although there have been extensive studies on multiscale modeling of cancer from molecular level to tumor level in the past decade, drug effect modeling has mostly remained at the pharmacokinetic/pharmacodynamic (PK/PD) characterization in modern pharmacotherapy without any multiscale consideration and integration with existing multiscale tumor studies. Thus, there is a need to develop multiscale computational models which cover the divide between organism-level PK/PD model and cell-level biochemical models.

Multiscale modeling deals with integrating information at multiple temporal and spatial scales and at various levels of biochemical complexities as summarized in Figure 1. It involves linking data resulting from the studies of molecules, cell, tissue, organ, organism, and population.1 Multiscale modeling has been widely touted as being exceedingly challenging with few successes but many failures.2 However, successes typically have a great impact as depicted by the application of multiscale modeling of the human heart to patient care,3 clinically driven design of multiscale modeling of cancers (eg, nephroblastoma, lung cancer, and glioblastoma multiforme),4,5 multiscale modeling of the progression of breast cancer,6 multiscale modeling of the development of cancer in epithelial tissues,7 and so on.

It is possible that the levels or scales on which cancer acts in some domains have relatively little to do with the canonical molecule, organelle, cell, tissue, tumor, or body hierarchy. Some cancer regimes (perhaps most, given the gene network analyses of several of the publications of the Cancer Genome Atlas project) may have an inherent network level of action (ie, the aggregate behavior of ∼10 genes in each of ∼15 gene networks). If so, at the gene level, carcinogenesis is often not meaningfully decomposable to the actions of network components (the individual genes) or localizable in the above canonical hierarchy. Sensitivity analyses can help to reveal these emergent features. However, it is also noticed that this phenomenon does not contradict with the multiscale modeling framework that links the entities at different scales, only that the entity may be a set of genes rather than an individual gene.
This review of multiscale models is from the system’s pharmacology perspective. System pharmacology is a vast area of study that deals with the applying knowledge of systems biology in combination with large-scale experiments and model-based computational analysis in the studies of drug effects, targets, and activities as well as the dynamics of drug interactions with biological systems. More concisely, multiscale modeling with drug effects integrates PK/PD drug models with phenomena at two or multiple temporal and spatial scales such as signaling networks, drug interactions, physiological processes operating at the tissue and organ level as well as animal models or clinical information. In other words, it is aimed at understanding the dynamics and evolution of a true multiscale model with PK/PD or integrative pharmacological perturbations through experiments and mathematical or computational analysis.

Currently, drug efficacy improvement is a critical research need, and this implies the identification of a new or better therapeutic targets. In recent years, there has been an increasing usage of molecularly targeted agents (MTAs) for cancer treatment. MTA design enables the interruption of vital components of crucial pathways in the system. MTAs are used to enhance the selectivity and efficacy by interfering with specific-targeted molecules needed for carcinogenesis and tumor growth. Although the lack of precision of the traditional cytotoxic drug allowed a rather direct approach in preclinical and clinical study, developing a paradigm that will better evaluate MTA efficacy is substantially more complicated. Moreover, complex diseases, such as cancer, involve the interaction of more complicated and dynamical biological systems. Thus, it is important to quantify drug effectiveness regarding different dosing regimens, optimal target(s), and combinational therapy at multiple scales of biochemical complexities.

The rationale of integrating multiscale modeling with drug effects is to link PK and PD information with experimental design (at cell population level and tumor level) in order to establish and evaluate dose-concentration–response relationships and subsequently describe and predict the effect-time courses resulting from a drug dose, while taking into account the underlying biological regulatory networks (at the molecular level). There are several challenges in this regard, namely:

- Selecting a model with manageable complexity, while not losing critical information.
• Accurate model parameter identification.
• Experimental validation of the proposed model.

The approach to tackle these challenges is as follows: (1) at the cell population level, study the response of a population of cells to various drugs and quantify the drug efficacy from experimental data; (2) use stochastic hybrid systems (SHSs) theory to link the drug efficacy obtained at the cell population level to pathways of interest at the molecular level; (3) extend the model to integrate the drug administration at the tumor level; and (4) improve the experimental design and drug intervention optimization iteratively while refining the multiscale drug effect model. Further discussions are given in the “Computational multiscale models incorporating PK/PD drug effect” section.

The need for a paradigm shift to the integration of multiscale models with drug development in relation to PK/PD or integrative pharmacological information is evident, as partly corroborated by various National Institute of General Medical Sciences workshops tagged as Quantitative and Systems Pharmacology I and II. The workshops were organized for the purpose of deliberating on the impact and contributions of systems biology to drug discovery and development as well as the current and future understanding of drug actions. Interested readers may refer to Ref. 29 for details.

The remainder of this paper is outlined as follows: the “Fundamental multiscale models” section presents a review of the fundamental multiscale models, while the “Multiscale models incorporating drug effects” section focuses on multiscale models incorporating drug effects. An example of a multiscale model using SHSs with PK/PD and the evaluation of drug effects is reviewed in the “Computational multiscale models incorporating PK/PD drug effect” section. Finally, this paper is concluded in the “Conclusions” section.

### Fundamental Multiscale Models

We present example studies on general multiscale modeling for cancer and then later move on to multiscale modeling works incorporating drug effects. This review aims to complement excellent reviews such as Refs 1, 19, 30–38 in the literatures but from a slightly different perspective. This is due to the common belief that cancer and tumor growth are complex biological phenomena. The complexity can be best understood and tackled by employing a multifaceted approach that may involve in vivo and in vitro experiments, in silico models, multiscale tumor modeling, continuous/discrete modeling, agent-based modeling, and multiscale modeling with PK/PD drug effect inputs (which is the main focus of this review). A summary of the sample studies on multiscale models for cancer in terms of application areas and methodologies used is provided in Table 1.

A review of important and recent works on multiscale cancer models that span two or more spatiotemporal biological scales and those that have successfully studied tumor angiogenesis, invasion, progressions, and metastasis from a truly

---

**Table 1. Sample multiscale modeling researches (with and without system pharmacology considerations) based on application areas and methodology used.**

| RESEARCH WORKS | APPLICATION AREAS | METHODOLOGY |
|----------------|------------------|-------------|
| **A. Examples of multiscale modeling study incorporating drug effects** |
| Clinically driven design of multiscale cancer models: The contracancrum project paradigm, Marias et al. (2011) | Glioblastoma, Multiforme, lung cancer, in silico oncology, tumor research | Continuum-based method, theory of reaction-diffusion, discrete event model using cell clustering into equivalent classes, Monte Carlo approach, cellular automata and dedicated algorithms |
| Multiscale cancer modeling and in silico oncology: Emerging computational frontiers in basic and translational cancer research, Stamatelatos et al. (2013) | Drug target discovery, drug discovery and development | In silico Cross-scale Agent Based analytical techniques |
| Discovering molecular targets in cancer with multiscale modeling, Wang et al. (2011) | Colon cancer, drug effect modeling | Stochastic hybrid system model with Markov jumps |
| Drug effect study on proliferation and survival pathways on cell line-based platform: A stochastic hybrid systems approach | Drug development | Ordinary differential equations |
| Multiscale mathematical modeling to support drug development, Nordsletten et al. (2011) | Pathway modeling, model repositories with PK/PD considerations, yeast glycolytic network | Robustness analysis, Nonlinear (weighted) least-squares methods for parameter estimation |
| What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics/pharmacodynamics platform, Swat et al. (2010) | Drug action, genome medicine, disease treatment and prevention | High-level perspective paper, global drug analyses, network analysis |
| Systems pharmacology and genome medicine: A future perspective, Wist et al (2009) | | (Continued) |
multiscale perspective can be found in the study by Deisboeck et al.\textsuperscript{30} The work considered four major biological scales in space and time and the various modeling approaches in terms of continuum, discrete, and hybrid modeling techniques.\textsuperscript{39–45} There are diverse classifications of biological scales\textsuperscript{46} because of the diverse nature of the systems to be modeled. The central theme of the classifications is that a multiscale model should consider different scales in time and space that reasonably, predictively, and realistically capture the behavior of the biological system across the different scales from lower to higher scales or vice versa.\textsuperscript{47,48} The research community has tackled this challenging problem with different modeling and analytical or computational approaches. For instance, Marias et al.\textsuperscript{5,49} and Stamatakos et al.\textsuperscript{5,49} have performed a promising study on computational multiscale cancer models and \textit{in silico} oncology for basic and translational cancer research. They discussed multiscale cancer modeling and \textit{in silico} oncology as two disciplines that are addressing the challenges associated with the complexity, heterogeneity, and multifacetedness of cancer cells and have been able to clearly describe the common network analytical techniques used in the study of tumor invasion, proliferation, apoptosis, and metastasis.

Researchers have extensively studied the simulation of cancer growth with multiscale agent-based modeling.\textsuperscript{53,50,51} Genetic mutations have long been understood to be the primary cause of uncontrolled growth of cells, and this has prompted researchers to investigate the genes that are responsible for the growth of cells and the associated processes affected and regulated in tumorigenesis\textsuperscript{53} as well as their influence on the microenvironments and metastasis of tumors.\textsuperscript{53} Usually, different approaches such as wet-lab experiments and mathematical and computational models are employed to tackle the

| Table 1. (Continued) |
|----------------------|
| **RESEARCH WORKS**   | **APPLICATION AREAS** | **METHODOLOGY** |
| Systems approaches to polypharmacology and drug discovery, Boran et al (2010)\textsuperscript{19} Mathematical modeling in cancer drug discovery, Wang et al (2014)\textsuperscript{165} | Disease treatment, drug discovery | Literature review |
| **B. Examples of multiscale modeling works not incorporating drug effects** | | |
| Strategies and tactics in multiscale modeling of cell-to-organ systems, Bassingthwaighte et al (2006)\textsuperscript{99} Hierarchical reconstructions of cardiac tissue, poole et al (2002)\textsuperscript{100} | Physiology, cardiac performance | Linear-in parameter dynamic system model, ordinary and partial differential equations, cellular automata |
| Multiscale models of cell signaling, Sameer et al (2012)\textsuperscript{101} A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis, Janes et al (2005)\textsuperscript{102} Sachs et al (2005)\textsuperscript{103} | Cell signaling | Mass cytometry, bayesian theory, partial least square regression |
| Structural systems biology and multiscale signaling models, Telesco et al (2012)\textsuperscript{104} Heterogeneous multiscale method: A general methodology for multi-scale modeling, Engquist et al (2003)\textsuperscript{105} | Cell signaling, protein networks | Multiple methods reviewed such as hybrid multiscale method |
| Multiscale modeling in computational biomedicine, Sloot et al (2009)\textsuperscript{106} modeling the heart—from genes to cells to the whole organ, Noble (2002)\textsuperscript{2} Hunter et al (2008)\textsuperscript{46} Plank et al (2008)\textsuperscript{107} | Human immunodeficiency virus spreading and coronary artery disease, heart | Complex automation simulations, multiscale simulation library environ, continuum field concepts and temporal scale separation in systems of coupled ODEs |
| Multiscale computational models of complex biological systems, Walpole et al (2013)\textsuperscript{36} multiscale cancer modeling, Deisboeck et al (2011)\textsuperscript{38} In silico models of cancer, edelman et al (2010)\textsuperscript{39} Simulating cancer growth with multiscale agent-based modeling, Wang et al (2014)\textsuperscript{33} Geraldes et al (2009)\textsuperscript{36} Fedosov et al (2011)\textsuperscript{37} | Blood vessel wall, erythrocyte membrane, diabetic retinopathy, tumor modeling, cancer systems biology | Literature review |
| Multiscale models for gene network engineering, Kaznessis (2006)\textsuperscript{108} | Gene regulatory networks, biomolecular systems, oscillators | Multiscale hybrid algorithms |
| CytoSolve: A scalable computational method for dynamic integration of multiple molecular pathway models, Ayyadurai et al (2011)\textsuperscript{109} | Biomolecular multi-pathway modeling | Parallel simulations, CytoSolve software platform |
| Multiscale models of breast cancer progression, Chakrabarti et al (2012)\textsuperscript{28} | Breast cancer progression | Micro-fluidic and 3D tissue engineering platform development |
| Bioinformatics, multiscale modeling and the IUPS physiome project, Hunteret al (2008)\textsuperscript{46} Integration from proteins to organs: the Physiome project, Hunter et al (2003)\textsuperscript{110} | Heart and organ modeling, | XML markup languages: CellML for ODEs and algebraic equations, FieldML for PDEs. |
| Multiscale, multi-resolution brain cancer modeling, Zhang et al (2009)\textsuperscript{111} | Tumor progression and invasion, brain cancer modeling | Agent-based \textit{in silico} glioma modeling, Kinetic equations. |
complexity and multifacetedness of abnormal cell growth.\textsuperscript{54} The mathematical cancer models can be discrete, continuous, or hybrid.\textsuperscript{30,40,41,55–57} Wang et al.\textsuperscript{53} reviewed the most current multiscale agent-based modeling (ABM) of tumors that has elucidated the concept of tumor growth and invasions from a multiscale perspective. The study discusses the various hypotheses resulting from these modeling approaches as well as the challenges associated with these cancer ABMs. ABMs have successfully incorporated and investigated several aspects of the morphology of cancer cells, including angiogenesis, phenotype-altering mutation, extracellular matrix influences, responses to chemotherapy or surgery, availability of nutrients and effects of oxygen, adaptations to the microenvironment, metastasis, and invasions of normal tissues.\textsuperscript{30,40,41,55–57}

One example application of the potential of multiscale models of cancer is the study by Chakrabarti et al.\textsuperscript{6}, in which the authors present a multiscale model of breast cancer progression. They study multiscale modeling of breast cancer with the specific focus on integrating models based on intracellular signal transductions with procarcinogenic mechanical and chemical microenvironmental indications. The authors study the initiation, proliferation, and the basic biomolecular angiogenesis of breast cancer. They investigate modeling methods for different types of cancers as well as models specific to breast cancer with the long-term aim of identifying and validating potential therapeutic targets. For the identification and validation of multiscale simulations, the authors succinctly describe the integration of microfluidic and three-dimensional tissue engineering platform development that could be geared toward such an endeavor. Multiscale modeling has further been applied as a spatiotemporal computational model which integrates genetic evolution with spatial growth in predicting that migration and cell turnover limits heterogeneity within a tumor.\textsuperscript{58} The model is based on stochastic replication of cells having rates that are proportional to the values of the neighboring empty sites, thus suggesting that the growth rates of a tumor can be markedly affected by attacking the short-range dispersal activities of the tumor cells.\textsuperscript{58}

**Multiscale Models Incorporating Drug Effects**

Wang et al. have carried out a number of research studies on how multiscale models can be used in the identification of drug targets and combination therapy.\textsuperscript{50,51,59–61} The approach is based on quantifying the relations among intracellular Epidermal growth factor receptor (EGFR) signaling dynamics, extracellular Epidermal growth factor (EGF) stimuli, and multicellular growth in lung cancer. Multiscale modeling of tumors incorporated with system pharmacology will aid progress toward the development of practical smart drugs. It will result in an integrated system-level method of determining the dynamics of actions of existing and new drugs in preclinical trials, model organisms, and individual patients. In addition, the experimental, mathematical, and computational studies of biological networks in diseases and health will provide a better way to understand the multiple factors that influence the drug effects and thus will help in revealing better ways to therapeutically intervene in the pathophysiology of disease and also reduce toxicity to the minimum.\textsuperscript{29,62} The group has also been studying multiscale modeling for investigating huge malignant brain cancer as biosystems that are self-organizing and dynamically complex,\textsuperscript{63–66} which furtheres the argument for using multiscale modeling for interdisciplinary cancer research.

Researchers are currently working on multiple modeling approaches that promise to be integrative while linking different levels of biological complexities and biochemical details. For instance, differential equation models and extensive stochastic simulations have helped to clarify the origin of noise in the biological systems,\textsuperscript{67} the temporal and spatial dynamics of complicated signaling pathways,\textsuperscript{68} and the origin of variabilities in cellular response to drugs.\textsuperscript{69} Regression analytical models are used to explain more complex pathway models and to compare drug responses in diseased and normal cells.\textsuperscript{70,71} At another direction, bioinformatics and data mining techniques have been used to study the diversity in patient drug response.\textsuperscript{72} In a practical context, PK/PD models have remained as the foundation upon which drug discovery is based. Li et al. have carried out several studies in an attempt to link pathway and PK/PD modeling via hybrid systems modeling and the characterization of drug effects by PK/PD.\textsuperscript{18,24–26,73}

Of particular interest to this review is the study by Li et al.\textsuperscript{24} involving a multiscale integrative preclinical model that combines mathematical analysis and experiments in studying the pathway dynamics crucial to cancer cells when perturbed with drugs, thereby assessing the therapeutic effects of such drugs. The multiscale model bridges cell-level biochemical models and organism-level PK/PD models.

The imperative research needed today is the improvement of drug efficacy, which implies the identification of better or new targets and/or combinations of targets. This is predicated on better predictions, which depend on better computational models and measurements. Examples of multiscale models that incorporate molecular and cellular information with PK/PD models and studies of a tumor’s drug absorptions, distributions, and engagements of targets are given in Refs 18, 25, 26, 28.

The work by Li et al.\textsuperscript{24} has the potential to help in administering the appropriate dose and dosage regimens as well as the identification of patients who will respond well to new therapeutic drugs and/or drug combinations. The approach is to combine multiscale mathematical modeling of signaling and regulatory pathways with single-cell and multifaceted experimental data in order to grasp the exact biochemistry, functionality, and dynamics of the networks controlling regular cell physiology and implicated in disease. The work provides a detailed mathematical and computational approach to study and describe the dynamics and mechanisms of drug actions on tumor growth and diseased cells.\textsuperscript{18} It also provides
a systematic way of determining the best effective dose. An extension of the work will arm researchers with mathematical and systematic ways of understanding the mechanisms of drug action and adverse responses in a computational multiscale context, thereby improving the probability of success in new drug discovery. The ContraCancrum project paradigm has been focused on clinically driven design of multiscale cancer models. The project has been seeking to develop a multiscale cancer models that contribute to the clinical adaptations of predictive in silico oncology. It aims to optimize treatment of cancer in personalized medicine via the simulation of malignant tumor response to diverse therapeutic regimens. The project has developed an integrated software platform called IMENSE for uploading the various imaging, molecular, histological and treatment data. The data are acquired before and after the therapeutic procedure and they are compared with multi-level simulation predictions to aid clinical adaptation procedures. Marias et al. particularly focus on the design of an in silico multiscale tumor model, which is driven clinically. The study combines fundamental biomedical science with modules in information technology to initiate a lifelong clinical adaptation procedure of the model for glioblastoma multiforme and lung cancer (non-small cell). The modeling methodologies used include a continuum-based method that exploits the theory of reaction–diffusion, a discrete-event model exploiting cell clustering into equivalence classes, Monte Carlo approaches, cellular automata, and dedicated algorithms.

Furthermore, the ContraCancrum project team has developed the technological integrative oncosimulator, which combines multiscale cancer models with information technology within the in silico oncology framework. The work by Stamatakos et al. describes the in silico multiscale information technology integrated oncosimulator and its vital components and functions. The multiscale oncosimulator simulates therapeutic responses of tumors in vivo in the context of clinical trials, adaptations, and personalized medicine. The paper describes its use in the prediction of responses to chemotherapy in the cases of breast cancer and nephroblastoma. Validation of the oncosimulator is carried out by comparing its in silico prediction with preoperative and postoperative imaging information and clinical data. This is a step toward enabling multiscale models in systems medicine. The interdisciplinary and multiscale nature of systems medicine with respect to disease treatment, clinical practice, basic research and information technology infrastructure, and the exploitation of current data, mathematical analysis, computational approaches, and information technology for developing efficient multiscale models are discussed by Wolkenhauer et al.

Multiscale modeling has been used to explore the discovery of molecular targets in cancer. Wang et al. extensively studied the identification of molecular therapeutic targets of high value via multiscale modeling in combination with cross-scale agent-based analytical techniques and its associated challenges in terms of data heterogeneity, verification of model parameters, validation of model outputs, and computational complexity of more complicated models. They provided an in silico modeling approach that promises to give insight into the discovery of drug targets. The group has also studied global sensitivity analysis for multiscale mathematical cancer models, which helps in identifying crucial molecular-level parameters with substantial effect on microscopic-level tumor volume and rate of expansion.

The design of multiscale PK/PD models that is cell type specific for personalized patient care has been examined by Ballesta et al. and specifically applied to Temozolomide chemotherapy against brain tumor. The study provided a quantitative characterizations of Temozolomide brain dispositions in the patient using a physiological-based mechanistic modeling approach at the molecular level to determine the PKs of Temozolomide; the law of mass action was used to model the chemical reactions, and the law of diffusion was used to model the passive drug transportation. The overall modeling approach defined intracellular standard brains and brain tumors compartment, where Temozolomide pH-dependent conversions to the DNA-alkylating species resulted in forming DNA adducts that served as the entry point for the PD model. The study will help in personalizing Temozolomide chemotherapy and the development of optimal dosage schedules as well as the optimal combination of drugs for personalized medical care.

### Computational Multiscale Models Incorporating PK/PD Drug Effect

The modeling and characterization of drug effects at different scales and across scales have been reported by Li et al. Specifically, in a study by Li et al., the authors’ goal is to investigate the responses of cancer cell population to a variety of drugs that target the proliferations and survival pathways by proposing a multiscale model that combines dynamics of genetic regulation and cell population responses to drugs using SHS approach. For the validation of the model, they used the example of a colon cancer cell line HCT-116 with the application of the Lapatinib drug. At the time of the Translational Genomics Research Institute (TGen) experiments on HCT-116 cell line, the measure to determine whether the proliferation pathway at the cell population level is repressed is the percentage change in nonproliferating cells. For the linkage of this measure to the drug effects on the molecular level, an integrative pathway and cell population model were proposed based on SHS theory and the setup of the experiments at TGen.

The behavior of cancer can be modeled using discrete, continuous, or hybrid mathematical approaches. Discrete modeling can provide a spatiotemporal representation of individual cells and cell–cell interactions. The major disadvantage of this modeling approach is that the computation required increases as the number of cells being modeled grows and this limitation
Integrating multiscale modeling with drug effects for cancer treatment

confines the model to a very small number of cells. Continuous modeling is a good candidate for describing large-scale systems. It can capture large-scale dynamics of tumor growth and development at a lower computation cost but sacrifices the resolutions of individual cells, especially when the properties of the cell vary over little spatiotemporal scales.

Hybrid modeling combines the advantages of both discrete and continuous modeling methods, and is appealing for modeling genetic networks under drug perturbations because biological systems are naturally nonlinear, have highly varied regulatory requirements, and possess a wide range of control strategies for meeting their needs. In the case of pathway dynamics, we adopted the well-recognized model of the proliferation and the survival pathways using Ordinary Differential Equations (ODE).24

Another modeling approach is the S-system modeling rubric.88–91 The S-systems are described as systems of power-law-oriented, finite-difference differential equations cast in a canonical producer–consumer form, and their representations are mathematically equivalent to the generalized

| VARIABLE | PROTEIN OR COMPLEX | PATHWAY DYNAMICS |
|----------|-------------------|------------------|
| y(1)     | EGFR2             | \[
\frac{dy(1)}{dt} = \beta_1[EGFR][EGFR] - \alpha_1y(1)\eta_{Lap,1}S - \alpha_{12}y(7) \]
| y(2)     | EGFR + ERBB2      | \[
\frac{dy(2)}{dt} = \beta_2[EGFR][ERBB2] - \alpha_2y(2)\eta_{Lap,2}S - \alpha_{10}y(7) \]
| y(3)     | ERBB2 + ERBB3     | \[
\frac{dy(3)}{dt} = \beta_3[ERBB2][ERBB3] - \alpha_{13}y(3)\eta_{Lap,3}S - \alpha_{11}y(7) \]
| y(4)     | RAS               | \[
\frac{dy(4)}{dt} = \alpha_4y(1)\eta_{Lap,1}S + \alpha_5y(2)\eta_{Lap,2}S - \alpha_{3}y(4) - \alpha_{4}y(4) \]
| y(5)     | RAF               | \[
\frac{dy(5)}{dt} = \alpha_{5}y(4) - \alpha_{5}y(10) - \alpha_{6}y(5) \]
| y(6)     | MEK               | \[
\frac{dy(6)}{dt} = \alpha_{6}y(5) - \alpha_{7}y(6) \]
| y(7)     | ERK               | \[
\frac{dy(7)}{dt} = \alpha_{7}y(6) - \alpha_{3}y(7) - \alpha_{9}y(7) - \alpha_{10}y(7) - \alpha_{11}y(7) - \alpha_{12}y(7) \]
| y(8)     | PI3K              | \[
\frac{dy(8)}{dt} = \alpha_{13}y(3)\eta_{Lap,3}S - \alpha_{14}y(8) + \alpha_{4}y(4) \]
| y(9)     | PDPK1             | \[
\frac{dy(9)}{dt} = \alpha_{14}y(8) - \alpha_{15}y(9) \]
| y(10)    | AKT               | \[
\frac{dy(10)}{dt} = \alpha_{15}y(9) - \alpha_{3}y(10) - \alpha_{16}y(10) \]
| y(11)    | mTOR              | \[
\frac{dy(11)}{dt} = \alpha_{16}y(10) - \alpha_{7}y(11) \]
| y(12)    | RP6SKB1           | \[
\frac{dy(12)}{dt} = \alpha_{7}y(11) + \alpha_{9}y(7) - \alpha_{18}y(12) \]
| y(13)    | FOS               | \[
\frac{dy(13)}{dt} = \alpha_{6}y(7) + \alpha_{18}y(12) - \alpha_{19}y(13) \]
| \eta_{Lap,S} | drug coeff. | \[
\eta_{Lap,S} = \begin{cases} 1 & \text{S is OFF} \\ \eta_{Lap} & \text{S is ON} \end{cases} \]
| S        | switch            | \[
M = \begin{pmatrix} 1 - m_0 & m_0 \\ m_1 & 1 - m_1 \end{pmatrix} \]
Lotka–Volterra schema. Any system of ordinary differential equations can be recast (although not uniquely) as an S-system. S-systems have many attractive mathematical properties that permit one to freely merge varying levels of abstraction with the assumption that flux conservations are respected. Specifically, an S-system modeling method could be employed in unifying the representations of gene regulations, molecular mass action-oriented kinetics, and population dynamics.

The approach adopted by Li et al follows an SHS modeling framework with the dynamics as shown in Table 2. Specifically, they considered the case where the drug effect coefficients are stochastic with the switching mechanisms following a Markov chain as shown in Figure 2.

The proliferation and the survival pathway, which biologists presently understand, for instance, the Kegg collection of pathways (http://www.genome.jp/kegg/pathway.html) and NIH BioCarta pathways collections http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways, are given in Table 2 together with input from the drug Lapatinib. The drug effects are introduced to the switch by affecting \(m_1\) (\(m_0\)).

\[
m_0 = \frac{\gamma}{1 + \gamma}, \quad m_1 = \frac{\gamma}{1 + \gamma}
\]  (1)

where \(\gamma\) the drug effect coefficient, is affected by PK/PD. In the simulation study, the proposed model was validated via a baseline run of the pathway model, and the output of the combined model was compared with the results from the experiments at TGen. It is observed from the baseline run of the gene expression levels in Figure 3 that Lapatinib suppressed the proliferation of the cancer cells, as indicated by the (Extracellular signal-regulated kinases [ERK]) level. It is interesting to note that the survival pathway is not suppressed. At the beginning of applying the drug, the concentration level of (Phosphoinositide 3-Kinase [PI3K]) decreases. However, it quickly recovers due to the cross-talk and feedback loops in the pathways. The simulation result shown in Figure 4 is similar to those observed in the series of experiments carried out on cancer cell lines at TGen. The observation is that Lapatinib repressed the cancer cells from proliferating and there exists a slow start for the first 10–15 hours, then a linear segment, and later after 30 hours a saturation in response as equally observed in the experiments at TGen.

An immediate extension of the work is the identification of the model parameters and the validation of the model across various drugs and cancer cell lines, but the model has to be carefully examined so as not to under- or overfit the parameters of interest. These phenomena are mostly relevant to multiscale integrated models in which there is a risk of propagating errors across scales and between models. The other challenge with this is that the model is more closely related to linear systems with markov jumps, and our understanding of such systems is not as thorough as those of linear systems, bilinear systems, or SHSs.

**Figure 2.** Schematics of the multiscale model used by Li et al. \(\rho\) is the nonproliferating cells ratio, \(\beta\) is the balancing factor that models extra variabilities such as logistic constraint, \(\gamma\) is the drug effect coefficient, [ERK] denotes the mean concentration level of ERK in cells. \(\alpha\) and \(\chi\) are the gene expression (protein) levels, \(\alpha_i > 0\) and \(\alpha_i < 0\) are the degradation and synthesis rates, respectively. \(\eta_{\text{drug}}\) is the drug effects factor. The expected impact of Lapatinib is the suppression of the Rapidly Accelerated Fibrosarcoma (RAF)/RAS pathway or reduces the concentration level of [ERK] and thus, the prevention of cancer cells from proliferation.

**Conclusions**

In this paper, we review multiscale modeling for cancer treatment with the incorporation of drug effects from a quantitative system’s pharmacology perspective. We believe that tumorigenesis and tumor growth can be best understood and tackled by employing and integrating a multifaceted approach. This includes *in vivo* and *in vitro* experiments, *in silico* models, multiscale tumor modeling, continuous/discrete modeling, agent-based modeling, and multiscale modeling with PK/PD drug effect inputs. Multiscale modeling approaches incorporating PK/PD information or drug effects will aid progress toward integrative personalized medicine, in which we can administer an optimal patient-specific nutritional or therapeutic regimen based on the
Integrating multiscale modeling with drug effects for cancer treatment

patient’s profiles and drug effects. Thus, this review focuses more on multiscale models that incorporated the drug effects. We provide an example application of multiscale modeling employing SHS for a colon cancer cell line HCT-116 with the application of Lapatinib drug. The simulation results are similar to those observed from the setup of the wet-lab experiments at TGen.

Author Contributions
XL, WO, LQ performed the literature review, developed and implemented the algorithm, conducted all simulations and data processing and wrote the initial draft of the paper. ED advised XL on algorithm development. All authors revised the paper. All authors read and approved the final manuscript.

REFERENCES
1. Gerdes MJ, Sood A, Sevinsky C, et al. Emerging understanding of multiscale tumor heterogeneity. Front Oncol. 2014;4:366.
2. Vicini P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin Pharmacol Ther. 2010;88(1):126–9.
3. Noble D. Modeling the heart – from genes to cells to the whole organ. Science. 2002;295:1678–82.
4. Stamatatos G, Dionysiou D, Lunzer A, et al. The technologically integrated oncosimulator: combining multiscale cancer modeling with information technology in the in silico oncology context. IEEE J Biomed Health Inform. 2014;18(3):840–54.
5. Maris K, Dionysiou D, Sakkalis V, et al. Clinically driven design of multiscale cancer models: the ContraCancerum project paradigm. Interface Focus. 2011;1(3):450–61.
6. Chakrabarti A, Verbridge S, Strock A, et al. Multiscale models of breast cancer progression. Ann Biomed Eng. 2012;40(11):2488–500.
7. Botet J, Mekuria D, Zaitsev A, et al. Multiscale modeling of tumor growth induced by circadian rhythm disruption in epithelial tissue. J Biol Phys. 2015:1–26.
8. Kohl P, Crampin EJ, Quinn TA, et al. Systems biology: an approach. Clin Pharmacol Ther. 2010;88(1):25–33.
9. Agoran BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007;12(23–24):1018–24.
10. Berger SI, Ma’ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal. 2010;3(118):1–5.
11. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res. 1999;16(2):176–85.
12. Van Der Graaf P, Benson N. systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011;28:1460–4.
13. Van Der Graaf P, Gabrielsson J. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Med Chem. 2009;1(8):1317–4.
14. Gabrielsson J, Dolgos H, Gillberg P-G, et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today. 2009;14(7–8):558–72.
15. Systems biology: a vision for engineering and medicine. a report from the academy of medical sciences and the royal academy of engineering; 2007. Available at: http://raeng.org.uk/policy/engagement/pdf/systems_biology_report.pdf.
16. Gabrielsson J, Fjelstrom O, Ulander J, et al. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr Top Med Chem. 2011;11:404–18.
17. Berg J, Rogers M, Lyster P. Systems biology and pharmacology. Clin Pharmacol Ther. 2010;88:17–9.
18. Li X, Qian L, Bittner ML, et al. A systems biology approach in therapeutic response study for different dosing regimens – a modeling study of drug effects on tumor growth using hybrid systems. Cancer Inform. 2012;11:41–60.
19. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010;13(3):297–309.
20. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175–81.
21. Qian L, Li X, Dougherty E. Robust identification of molecularly targeted drug effect coefficient using H∞ filter. In: Global Conference on Signal and Information Processing (GlobalSIP); 2013 IEEE. Austin, Texas. IEEE. 2013:99–102.
22. Li X, Qian L, Hua J, et al. Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. BMC Genomics. 2012;13(6):S11.
23. Li X, Qian L, Bittner ML, et al. Assessing the efficacy of molecularly targeted agents by using Kalman filter. In: GENISPs. San Antonio, Texas. IEEE. 2011.

Figure 3. A baseline run of the proliferation and the survival pathway with HCT-116 cancer cell line and input of Lapatinib.

Figure 4. The result of the simulations of the percentage change in nonproliferating cells versus the time for which Lapatinib was applied to the HCT-116 cancer cell line.
30 | CANCER INFORMATICS 2015;14(S5)

24. Li X, Qian L, Bittner M, et al. Drug effect study on proliferation and survival pathways on cell line-based platform: a stochastic hybrid systems approach. In: IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), 2013, Houston, Texas. IEEE. 2013:54–7.

25. Li X, Qian L, Bittner ML, et al. Characterization of drug efficacy regions based on dosage and frequency schedules. IEEE Trans Biomed Eng. 2010;57(8):1688–98.

26. Li X, Qian L, Dougherty E. Dynamical modeling of drug effect using hybrid systems. EURASIP J Bioinform Syst Biol. 2012;12:92.

27. Zhang L, Pfister M, Mebhoom B. Concepts and challenges in quantitative pharmacology and modeling in drug development. Am J Pharm biotech. 2008;10(4):522–9.

28. Luo F, Ju G, Zhan X, et al. Multiscale modeling of drug-induced reducing effects of refeeding on human disease: from drug molecules to clinical symptoms of disease. Sci Rep. 2015;5(6):1–15.

29. Quantitative and Systems Pharmacology Workshop II. Available at: http://biosign-cure.grc.nist.gov/Biosign/Research/HomeBiosign.html.

30. Deisboeck TS, Wang Z, Macklin P, et al. Multiscale cancer modeling. Annu Rev Biomed Eng. 2011;13(1):127–55.

31. Southern J, Pirt-Frans J, Whiteley J, et al. Multi-scale computational modeling in biology and physiology. Prog Biophys Mol Biol. 2008;96(l):60–89.

32. Gribah M, Mac Ghaith M, Karajaziannis E, et al. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag. 2009;28(2):14–31.

33. Wang Z, Butner JD, Kerketta R, et al. Simulating cancer growth with multiscale agent-based modeling. Semin Cancer Biol. 2015;30:70–8.

34. Walpole J, Papin JA, Peirce SM. Multiscale computational models of complex biological systems. Ann Biomed Eng. 2013;41:135–54.

35. Edelman LB, Eddy JA, Price ND. In silico models of cancer. Wiley Interdiscip Rev Syst Biol Med. 2010;2(4):438–59.

36. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2008;14:298–306.

37. Fedosov D, Lei H, Caswell B, et al. Multiscale modeling of red blood cell mechanics and blood flow in malaria. PLoS Comput Biol. 2011;7(12):e1002270.

38. Schadt E, Buchanan S, Brennam K, et al. Evolving towards a human-cell-based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol. 2014;5:252.

39. Anderson A, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer. 2008;8:227–34.

40. Lowengrund J, Friebos H, Jin F, et al. Nonlinear modeling of cancer: bridging the gap between micro- and macroscopic phenomena. Nat Methods. 2010;7:931–9.

41. Trapciak P. Biophysical models of tumour growth. Rep Prog Phys. 2009;72:056701.

42. Gatenby R, Silva A, Gillies R, et al. Adaptive therapy. Cancer Res. 2009;69:4894–903.

43. Wang Z, Deisboeck T. Computational modeling of brain tumors: discrete, continuum or hybrid: Sci Model Simul. 2008;15:381–93.

44. Schaller G, Meyer-Hermann M. Continuous vs. discrete model: a comparison for multicellular tumour spheroids. Philos Trans R Soc Lond Ser A. 2006;364:1443–64.

45. Berg O, Paulsson J, Ehrenberg M. Fluctuations and quality of control in biological systems. Nat Rev Genet. 2004;5:132–6.

46. Hunter P, Crampin E, Nielsen P. Bioinformatics, multiscale modeling and the gap between cells and tumours. PLoS Comput Biol. 2010;6:252.

47. Mansury Y, Deisboeck TS. The impact of search precision in an agent-based model of tumour invasion. Nonlinear Dyn. 2014;75:423–32.

48. Gascongke KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cells. 2008;8:111–22.

49. Swanson KR, Carly Bridge B, Murray JD, et al. Virtual and real brain tumors: some operator properties. Theor Biol Med Model. 2014;11(6):007.

50. Dionysiou DD, Stamatakos GS. Applying a 4D multi-scale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and $p_3$ gene status on the response of fast growing solid tumors. Cancer Res. 2008;68(10):3469–74.

51. Wang Z, Deisboeck T. Multiscale modeling and treatment effect at the molecular level using hybrid system theory. In: IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CICBB), 2010, Montreal, QC. 2010:1–7.

52. Stamatkos GS, Kolokotrontsi E, Dionysios DD, et al. An advanced discrete state discrete event multi-scale simulation model of the response of a solid tumor to chemotherapy. In: In Vivo. 2010;4:115–24.

53. Sakkalis V, Sfakianakis S, Tzamali E, et al. Web-based workflow planning platform supporting the design and execution of complex multiscale cancer models. IEEE Trans Biomed Eng. 2008;55(9):1830–6.

54. Rejniak K, Anderson A. Hybrid models of tumor growth. Wiley Interdiscip Rev Syst Biol Med. 2011;3:e114.

55. Rubinacci S, Graudenzi A, Caravagna G, et al. Cognac: a chaste plugin for the analysis of systems models. PLoS Comput Biol. 2013;9(5):e1003116.
Integrating multiscale modeling with drug effects for cancer treatment

86. Ballesta A, Zhou Q, Zhang X, et al. Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. *CPT Pharmacometrics Syst Pharmacol.* 2014;3(4):1–11.

87. Hua J, Sima C, Cypert M, et al. Tracking transcriptional activities with high-throughput epifluorescent imaging. *Biomed Optics.* 2012;17(4):1–15.

88. Voit EO. Modelling metabolic networks using power-laws and s-systems. *Essays Biochem.* 2008;45:29–40.

89. Voit EO. Computational Analysis of Biochemical Systems: A Practical Guide for Biochemists and Molecular Biologists. Cambridge: Cambridge University Press; 2000.

90. Voit EO. Computational Analysis of Biochemical Systems. A Practical Guide for Biochemists and Molecular Biologists. Cambridge: Cambridge University Press; 2006.

91. Wang H, Qian L, Dougherty E. Inference of gene regulatory networks using S-system: a unified approach. In: *IEEE Symposium on Computational Intelligence and Bioinformatics and Computational Biology.* 2007; CIBCB '07. Honolulu, HI. IEEE 2007:82–9.

92. Hu J, Lygeros J, Sastry S. Towards a theory of stochastic hybrid systems. *Lynch, N and Krogh, B, Editors. Hybrid Systems: Computation and Control, Ser. Lecture Notes in Computer Science.* Vol 1790. Berlin: Springer; 2000:160–73.

93. Bujorianu M, Lygeros J. General stochastic hybrid systems: modelling and optimal control. In: *43rd IEEE Conference on Decision and Control.* The Atlantis, Paradise Islands. IEEE. 2004;(2):1872–7.

94. Lincoln P, Tiwari A. Symbolic systems biology: hybrid modeling and analysis of biological networks. In: Altay R, Pappas GJ, eds. *Hybrid Systems: Computation and Control HSCC.* Vol 2993. Berlin: Springer; 2004:660–72.

95. Ghosh M, Arapostathis A, Marcus S. Ergodic control of switching diffusions. *SIAM J Control Optim.* 1997;35(6):1952–88.

96. Nordström D, Yankama B, Unetov R, et al. *Multiscale mathematical modeling to support drug development.* *IEEE Trans Biomed Eng.* 2011;58(12):3508–12.

97. Swat M, Kielbasa SM, Polak S, et al. What it takes to understand and cure a living system: computational systems biology and systems biology-driven pharmacokinetics/pharmacodynamics platform. *Interface Focus.* 2010;4(1):16–23.